Compare DSY & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSY | XFOR |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.1M | 324.4M |
| IPO Year | N/A | N/A |
| Metric | DSY | XFOR |
|---|---|---|
| Price | $0.27 | $4.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 156.8K | ★ 943.0K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.37 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $7,323,356.00 | ★ $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $22.56 | ★ N/A |
| Revenue Growth | 16.37 | ★ 2925.74 |
| 52 Week Low | $0.24 | $1.35 |
| 52 Week High | $7.33 | $26.83 |
| Indicator | DSY | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 23.85 | 57.54 |
| Support Level | $0.26 | $3.50 |
| Resistance Level | $0.34 | $4.56 |
| Average True Range (ATR) | 0.03 | 0.30 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 27.73 | 66.05 |
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.